P184 Differential pathologic response from primary systemic chemotherapy across breast cancer intrinsic subtypes
نویسندگان
چکیده
منابع مشابه
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
PURPOSE The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain. METHODS Tumor response at surgery and its association with long-term outcome of 6,377 patients with primary breast cancer receiving neoadjuvant anthracycline-taxane-based chemotherapy in seven randomized trials were analyzed. RESULTS Dise...
متن کاملIntrinsic Subtypes of Primary Breast Cancer--Gene Expression Analysis.
Intrinsic subtypes based on gene expression have substantially improved the understanding of the biological diversity and heterogeneity of breast cancer. The efficacy of adjuvant therapies depends on the level of risk for an individual patient. Because of this, careful estimation of the level of risk is mandatory. In addition to well-established clinicopathological factors, validated gene expre...
متن کاملResponse and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
BACKGROUND Predicting treatment benefit and/or outcome before any therapeutic intervention has taken place would be clinically very useful. Herein, we evaluate the ability of the intrinsic subtypes and the risk of relapse score at diagnosis to predict survival and response following neoadjuvant chemotherapy. In addition, we evaluated the ability of the Claudin-low and 7-TNBCtype classifications...
متن کاملA marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.
PURPOSE To assess the prevalence of defective homologous recombination (HR)-based DNA repair in sporadic primary breast cancers, examine the clincopathologic features that correlate with defective HR and the relationship with neoadjuvant chemotherapy response. EXPERIMENTAL DESIGN We examined a cohort of 68 patients with sporadic primary breast cancer who received neoadjuvant anthracylcine-bas...
متن کاملDifferential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
PURPOSE The clinical relevancy of the 7-subtype classification of triple-negative breast cancer (TNBC) reported by Lehmann and colleagues is unknown. We investigated the clinical relevancy of TNBC heterogeneity by determining pathologic complete response (pCR) rates after neoadjuvant chemotherapy, based on TNBC subtypes. EXPERIMENTAL DESIGN We revalidated the Lehmann and colleagues experiment...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Breast
سال: 2011
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(11)70126-6